All In Biotech

Drug Trial Radar · NCT06555640

A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous Injection of DR10624 in Subjects With Severe Hypertriglyceridemia

Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

79

Actual

Start

Aug 1, 2024

Primary completion

Jun 30, 2025

Study completion Aug 29, 2025

Sponsor

Sponsor type
Industry
First posted
Aug 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 17 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

DR10624 is an Fc fusion protein tri-agonist with balanced glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR)/ fibroblast growth factor 21 receptor (FGF21R) agonizing activities. The objectives of the planned clinical investigation will be to evaluate the efficacy of DR10624 on fasting serum triglyceride (TG) levels after 12 weeks of treatment in subjects with severe hypertriglyceridemia (SHTG).

Conditions

  • Severe Hypertriglyceridemia

Interventions

  • DR10624 InjectionDrug

    Drug: DR10624 injection

  • PlaceboDrug

    Drug: placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change of fasting TGTime frame: From baseline to Week 12

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Baoding No.1 Central Hospital

    Baoding, China

  • The First Affiliated Hospital of Baotou Medical College

    Baotou, China

  • Peking University First Hospital

    Beijing, China

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, China

  • The First Hospital of Jilin University

    Changchun, China

  • The Second Hospital of Jilin University

    Changchun, China

  • Second Xiangya Hospital of Central South University

    Changsha, China

  • Chifeng Municipal Hospital

    Chifeng, China

  • Daqing People's Hospital

    Daqing, China

  • The Affiliated Hospital of Hangzhou Normal University

    Hangzhou, China

  • The Fourth Hospital of Harbin Medical University

    Harbin, China

  • The First Affiliated Hospital of South China University

    Hengyang, China

  • Inner Mongolia People's Hospital.

    Hohhot, China

  • Huzhou Central Hospital

    Huzhou, China

  • Lishui Municipal Central Hospital

    Lishui, China

  • Luoyang Third Peoples Hospital

    Luoyang, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, China

  • Meihekou Central Hospital

    Meihekou, China

  • The Second Affiliated Hospital to Nanchang University

    Nanchang, China

  • The Third Hospital of Nanchang

    Nanchang, China

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, China

  • The Affiliated Hospital of Nantong University

    Nantong, China

  • Nanyang Central Hospital

    Nanyang, China

  • Panjin Liaoyou Baoshihua Hospital

    Panjin, China

  • Pingxiang People's Hospital

    Pingxiang, China

  • The People's Hospital of Liaoning Province

    Shenyang, China

  • Shaanxi Provincial People's Hospital

    Xi'an, China

  • The Third Affiliated Hospital of Xinjiang Medical University

    Xinxiang, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, China

  • Yancheng First People's Hospital

    Yancheng, China

  • Yixing People's Hospital

    Yixing, China

  • Yiyang Central Hospital

    Yiyang, China

  • Yueyang Central Hospital

    Yueyang, China

  • Yuncheng Central Hospital

    Yuncheng, China

  • Zibo Municipal Hospital

    Zibo, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.